Investor Relations Captor Therapeutics ®
Update on terminated grant agreement with NCBiR for CT-02 project
Current Report No. 27/2023
Date of preparation: 7 July 2023
Subject: Update on terminated grant agreement with NCBiR for CT-02 project
With reference to current report 21/2023 dated 6 June 2023 and current report 24/2023 dated 20 June 2023, The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the "Company") informs that the Company has today received from the National Centre for Research and Development ("NCBiR") a letter (the "Letter") in which NCBiR indicates that it has verified the documents sent by the Company and re-examined the matter in question and that the arguments and information contained in the letter submitted by the Company on 20 June 2023 (of which the Company informed in current report 24/2023) do not affect NCBiR's position. Accordingly, NCBiR maintains its position on the termination of the POIR.01.01.01-00-0741/19 agreement of 1 June 2020 with immediate effect with the return of the entire grant. The letter does not provide further justification for NCBiR's decision.
The Company intends to take further action to amicably resolve the dispute with NCBiR. On the other hand, in the event that such actions do not lead to an amicable resolution of the dispute, the Company expects to receive an administrative decision ordering the return of funds, which the Company intends to appeal against.
Other projects undertaken by the Company and funded by NCBiR are subject to ongoing evaluation by NCBiR and the Company is not aware of any objections to questioning the progress of the other projects.
The Company will report on further issues relating to the CT-02 project and the subject of this report as required by law.